This study will assess the efficacy, safety, and tolerability of 2 different doses of collagenase clostridium histolyticum (CCH) (previously known as EN3835) compared to placebo.

Key Inclusion Criteria:

• Have no significant medical history or examination findings related to the foot to be treated, which in the investigator's opinion, would make the participant unsuitable for study intervention administration.
• Have a diagnosis of plantar fasciitis for ≥6 months, which has not responded to conservative therapies. Conservative therapies may include rest, physical therapy, splinting/bracing, orthotics, icing, physiotherapy, acetaminophen, corticosteroids, or nonsteroidal anti-inflammatory drugs (NSAIDs).
• Have current foot pain due to plantar fasciitis.

Key Exclusion Criteria:

• Has any musculoskeletal, neuromuscular, neurosensory, other neurological or related disorder that affects the participant's use of his/her feet and/or would impair his/her completion of study assessments as determined by the investigator either due to the disorder or due to pain.
• Has a clinically meaningful laboratory abnormality.
• Has a body mass index ≥35 kilograms per meter squared (kg/m^2).
• Has a known bleeding disorder, which, in the investigator's opinion, would make the participant unsuitable for enrollment in the study.